Portal de Periódicos da CAPES

Examination of the Relationship Between Symptoms of Prostatitis and Histological Inflammation: Baseline Data From the REDUCE Chemoprevention Trial

2007; Lippincott Williams & Wilkins; Volume: 178; Issue: 3 Linguagem: Inglês

10.1016/j.juro.2007.05.041

1527-3792

J. Curtis Nickel, Claus G. Roehrborn, Michael P. O’Leary, David G. Bostwick, Matthew C. Somerville, Roger S. Rittmaster,

Genital Health and Disease

No AccessJournal of UrologyAdult urology1 Sep 2007Examination of the Relationship Between Symptoms of Prostatitis and Histological Inflammation: Baseline Data From the REDUCE Chemoprevention Trial J. Curtis Nickel, Claus G. Roehrborn, Michael P. O'Leary, David G. Bostwick, Matthew C. Somerville, and Roger S. Rittmaster J. Curtis NickelJ. Curtis Nickel Department of Urology, Queen's University, Kingston General Hospital, Kingston, Ontario, Canada , Claus G. RoehrbornClaus G. Roehrborn Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas , Michael P. O'LearyMichael P. O'Leary Division of Urology, Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts , David G. BostwickDavid G. Bostwick Bostwick Laboratories, Glen Allen, Virginia , Matthew C. SomervilleMatthew C. Somerville GlaxoSmithKline, Research Triangle Park, North Carolina , and Roger S. RittmasterRoger S. Rittmaster GlaxoSmithKline, Research Triangle Park, North Carolina View All Author Informationhttps://doi.org/10.1016/j.juro.2007.05.041AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Symptoms of abacterial chronic prostatitis/chronic pelvic pain syndrome are considered to be associated with prostate inflammation. The ongoing Reduction by Dutasteride of Prostate Cancer Events trial is a 4-year, phase III, placebo controlled study to determine whether 0.5 mg dutasteride daily decreases the risk of biopsy detectable prostate cancer. All men underwent biopsy before study entry, allowing review of the relationship between histological prostate inflammation and prostatitis symptoms. Materials and Methods: Eligible men were 50 to 75 years old with serum prostate specific antigen 2.5 ng/ml or greater and 10 ng/ml or less (ages 50 to 60 years), or 3.0 ng/ml or greater and 10 ng/ml or less (older than 60 years), and an International Prostate Symptom Score of less than 25 (or less than 20 if already on α-blocker therapy). Acute prostatitis was an exclusion criterion. The National Institutes of Health Chronic Prostatitis Symptom Index was used to assess prostatitis-like symptoms. Spearman rank correlations were used to assess the relationship between acute and chronic inflammation, and Chronic Prostatitis Symptom Index scores for the pain, urinary symptoms and quality of life domains as well as average pain, total score and prostatitis-like symptoms. Results: Data were available on 5,597 patients. The distribution of inflammation status was similar for those with and without chronic prostatitis-like symptoms. Significant correlations were found between average chronic inflammation, and total Chronic Prostatitis Symptom Index score and subscores for urinary symptoms and quality of life but the magnitude of these correlations was small. Conclusions: A lack of clinically meaningful association was found between prostatitis-like pain symptoms and histological inflammation in the Reduction by Dutasteride of Prostate Cancer Events population, suggesting that the view that symptoms of chronic prostatitis/chronic pelvic pain syndrome and prostate inflammation are associated needs further scrutiny. References 1 : NIH consensus definition and classification of prostatitis. JAMA1999; 282: 236. Google Scholar 2 : The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol1999; 162: 369. Link, Google Scholar 3 : Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol1999; 162: 2014. Link, Google Scholar 4 : Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol2004; 172: 1314. Link, Google Scholar 5 : Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol2001; 165: 842. Link, Google Scholar 6 : Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int2001; 87: 797. Google Scholar 7 : Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol1979; 121: 755. Link, Google Scholar 8 : Prostatic inflammation in benign prostatic hyperplasia—the third component?. Can J Urol1994; 1: 1. Google Scholar 9 : Chronic prostatitis in benign prostatic hyperplasia. Br J Urol1971; 43: 333. Google Scholar 10 : The impact of acute and chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol, suppl2005; 173: 346. abstract 1277. Link, Google Scholar 11 : Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol2006; 40: 155. Google Scholar 12 : Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology2004; 64: 1098. Google Scholar 13 : Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology2000; 55: 892. Google Scholar 14 : Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol2003; 170: 818. Link, Google Scholar 15 : Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol2002; 168: 1048. Link, Google Scholar 16 : The three As of chronic prostatitis therapy: antibiotics, alpha-blockers and anti-inflammatories: What is the evidence?. BJU Int2004; 94: 1230. Google Scholar 17 : Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study. Urology1999; 53: 502. Google Scholar 18 : A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int2004; 93: 991. Google Scholar 19 : The influence of finasteride on the development of prostate cancer. N Engl J Med2003; 349: 215. Google Scholar © 2007 by American Urological AssociationFiguresReferencesRelatedDetailsCited byNaha U, Nickel J, Andriole G, Freedland S and Moreira D (2020) Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE StudyJournal of Urology, VOL. 205, NO. 3, (755-760), Online publication date: 1-Mar-2021.Nickel J, Freedland S, Castro-Santamaria R and Moreira D (2017) Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic PainJournal of Urology, VOL. 198, NO. 1, (122-128), Online publication date: 1-Jul-2017.Nickel J, Roehrborn C, Montorsi F, Wilson T and Rittmaster R (2011) Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE StudyJournal of Urology, VOL. 186, NO. 4, (1313-1318), Online publication date: 1-Oct-2011.Thumbikat P, Shahrara S, Sobkoviak R, Done J, Pope R and Schaeffer A (2010) Prostate Secretions From Men With Chronic Pelvic Pain Syndrome Inhibit Proinflammatory MediatorsJournal of Urology, VOL. 184, NO. 4, (1536-1542), Online publication date: 1-Oct-2010.Al-Ghamdi A, Lockwood G, Toi A, Kulkarni G, Evans A, Finelli A, Zlotta A and Fleshner N (2008) Extended Pattern Prostate Biopsy Does Not Minimize the Volume-Grade Bias in Prostate Cancer DetectionJournal of Urology, VOL. 179, NO. 4, (1332-1334), Online publication date: 1-Apr-2008. Volume 178Issue 3September 2007Page: 896-901 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsprostateurination disordersprostatitisinflammationbiopsyAcknowledgmentsAlexander Gray assisted with the manuscript. Diagnostic slides were reviewed at Bostwick Laboratories, Richmond, Virginia.MetricsAuthor Information J. Curtis Nickel Department of Urology, Queen's University, Kingston General Hospital, Kingston, Ontario, Canada Financial interest and/or other relationship with GlaxoSmithKline, Merck, Sanofi-Aventis, Farr Laboratories, Boston Scientific, Plethora Solutions and Threshold Pharma. More articles by this author Claus G. Roehrborn Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Michael P. O'Leary Division of Urology, Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author David G. Bostwick Bostwick Laboratories, Glen Allen, Virginia Financial interest and/or other relationship with GlaxoSmithKline, Genotherapeutics, Dendreon, Diagnocure, Endocare and Bostwick Laboratories. More articles by this author Matthew C. Somerville GlaxoSmithKline, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Roger S. Rittmaster GlaxoSmithKline, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Expand All Advertisement PDF downloadLoading ...